Assessing Amicus Therapeutics (FOLD) Valuation After A Strong 71% One Year Total Return [Yahoo! Finance]
Amicus Therapeutics, Inc. (FOLD)
Last amicus therapeutics, inc. earnings: 11/11 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.amicusrx.com/investor-relations
Company Research
Source: Yahoo! Finance
Amicus Therapeutics (FOLD) has drawn attention after recent share performance data highlighted a 71% total return over the past year, prompting closer scrutiny of how its rare disease portfolio and fundamentals align with current pricing. See our latest analysis for Amicus Therapeutics. While the recent 1-day and 7-day share price returns of around 0% suggest a pause, the 1-year total shareholder return of about 71% points to strong momentum that has built over a longer stretch as investors reassess Amicus Therapeutics' rare disease pipeline and risk profile. If Amicus Therapeutics has you looking more closely at healthcare names, it could be a good time to see which other drug developers are gaining attention through 34 healthcare AI stocks With a 71% 1 year total return, a value score of 5, and the share price sitting close to the US$14.50 analyst target, the question is whether FOLD still offers upside or if the market is already pricing in future growth. Most Popular Na
Show less
Read more
Impact Snapshot
Event Time:
FOLD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FOLD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FOLD alerts
High impacting Amicus Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FOLD
News
- Amicus Therapeutics (FOLD) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Assessing Amicus Therapeutics (FOLD) Valuation After Recent Share Price Momentum And DCF Upside [Yahoo! Finance]Yahoo! Finance
- Pombiliti (Amicus Therapeutics) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, Forecasts [Yahoo! Finance]Yahoo! Finance
- Genomenon and Amicus Therapeutics Partner to Advance Fabry Disease Awareness and Diagnosis [Yahoo! Finance]Yahoo! Finance
- Chris Duke joins RBL LLC leadership team as Operating Partner [Yahoo! Finance]Yahoo! Finance
FOLD
Earnings
- 2/20/26 - Beat
FOLD
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/4/26 - Form 4
- 3/3/26 - Form 8-K
- FOLD's page on the SEC website